Showing results (171-180 of 410) with videos related to
Sort By:
Pageof 41
Biochemical and Biophysical Research Communications|October 28, 2010
Isolation of tumorigenic circulating melanoma cellsJie Ma, Jennifer Y Lin, Allireza Alloo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Xiaoyun Liao, Lynette M Sholl, et al.Cancer Research Communications|December 20, 2023
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I StudyPamela Munster, Nicholas Iannotti, Daniel C Cho, et al.Melanoma Research|March 11, 2026
Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanomaAhmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, et al.Journal for Immunotherapy of Cancer|June 19, 2026
Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanomaAhmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, et al.Cancer Treatment Reviews|February 6, 2025
Diagnosis and management of bispecific T cell-engaging antibody toxicity: A primer for emergency physiciansMonica K Wattana, Jonathan Rowland, Aiham Qdaisat, et al.Cancer Immunology Research|June 18, 2016
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating LymphocytesVishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, et al.Pancreas|August 29, 2018
Characterization of the Neuroendocrine Tumor Immune MicroenvironmentAnnacarolina da Silva, Michaela Bowden, Sui Zhang, et al.Cancer Immunology Research|May 6, 2017
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical OutcomesXinqi Wu, Jingjing Li, Erin M Connolly, et al.Journal for Immunotherapy of Cancer|August 21, 2020
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) serviceOsama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, et al.Pageof 41